G-CSF (Granulocyte Colony Stimutating Factors) Market 2020 : Share Value Analysis of Top Key Players, Global Size, Consumption Analysis, Trends Forecast to 2030 | TBRC Reports

The Business Research Company offers " G-CSF (Granulocyte Colony Stimutating Factors) Global Market Report 2020-30: COVID-19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market’s historic and forecast growth, and highlights important trends and strategies that players in the market can adopt.

The global Granulocyte-Colony Stimulating Factor (G-CSF) is expected to decline from $7.30 billion in 2019 to $6.91 billion in 2020 at a compound annual growth rate (CAGR) of -5.27%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $8.33 billion in 2023 at a CAGR of 6.44%.

Place a DIRECT PURCHASE ORDER of The Entire 140+ Pages Report @
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3466

The G-CSF (Granulocyte Colony Stimulating Factors) market consists of sales of G-CSF drugs and relates services. Granulocyte colony-stimulating factor is a drug used to treat neutropenia, a disorder in which there is a lower-than-average number of white blood cells, caused by certain forms of chemotherapy.

The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is another key factor driving the growth of the granulocyte-colony stimulating factor market. The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is expected to drive the growth of the granulocyte-colony stimulating factor market.

G-CSF (Granolocyte Colony Stimutating Factors) Market Segmentation: -
By Type
Lenograstim (Granocyte)
Filgrastim (Neupogen, Zarzio, Nivestim, Accofil)
Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco)
Lipegfilgrastim (Lonquex)

By Application
Oncological Diseases
Blood Disorders
Growth Hormone Deficiencies
Chronic and Autoimmune Disorders
Others

Browse Complete Report @
https://www.thebusinessresearchcompany.com/report/g-csf-granulocyte-colony-stimutating-factors-global-market-report-2020-30-covid-19-growth-and-change

Few Points From Table Of Content
1. Executive Summary
2. G-CSF (Granolocyte Colony Stimutating Factors) Market Characteristics
3. G-CSF (Granolocyte Colony Stimutating Factors) Market Size And Growth
4. G-CSF (Granolocyte Colony Stimutating Factors) Market Segmentation
5. G-CSF (Granolocyte Colony Stimutating Factors) Market Regional And Country Analysis
.
.
.
25. G-CSF (Granolocyte Colony Stimutating Factors) Market Competitive Landscape And Company Profiles
26. Key Mergers And Acquisitions In The G-CSF (Granolocyte Colony Stimutating Factors) Market
27. G-CSF (Granolocyte Colony Stimutating Factors) Market Trends And Strategies
28. G-CSF (Granolocyte Colony Stimutating Factors) Market Future Outlook and Potential Analysis
29. Appendix

The report covers the trends and market dynamics of the G-CSF (Granolocyte Colony Stimutating Factors) Market in major countries - Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.

Request for a Sample Copy of This Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

Some of the key players involved in the G-CSF (Granolocyte Colony Stimutating Factors) Market are BioCad, Teva Pharmaceuticals, Pfizer, Intas Pharmaceuticals, Novartis AG, Stada Arzneimittel.

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Blog: http://blog.tbrc.info/

About US:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.

This release was published on openPR.